Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone

1999 ◽  
Vol 17 (6) ◽  
pp. 1654-1654 ◽  
Author(s):  
David Osoba ◽  
Ian F. Tannock ◽  
D. Scott Ernst ◽  
Alan J. Neville
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Global Quality ◽  
Global Quality Of Life ◽  
Related Quality ◽  
Health Related

PURPOSE: A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer. The purpose of this study was to assess the effects of these treatments on health-related quality of life (HQL). PATIENTS AND METHODS: Men with metastatic prostate cancer (n = 161) were randomized to receive either daily prednisone alone or mitoxantrone (every 3 weeks) plus prednisone. Those who received prednisone alone could have mitoxantrone added after 6 weeks if there was no improvement in pain. HQL was assessed before treatment initiation and then every 3 weeks using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ-C30) and the Quality of Life Module–Prostate 14 (QOLM-P14), a trial-specific module developed for this study. An intent-to-treat analysis was used to determine the mean duration of HQL improvement and differences in improvement duration between groups of patients. RESULTS: At 6 weeks, both groups showed improvement in several HQL domains, and only physicalfunctioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group. After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P = .009), four functioning domains, and nine symptoms (.001 < P < .01), and the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P < .05). The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P < .003). CONCLUSION: Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.

Health-related quality of life among patients with metastatic prostate cancer

Urology ◽  
1997 ◽  
Vol 49 (2) ◽  
pp. 207-217 ◽  
Author(s):  
Peter C. Albertsen ◽  
Neil K. Aaronson ◽  
Martin J. Muller ◽  
Susan D. Keller ◽  
John E. Ware
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Interpreting the significance of changes in health-related quality-of-life scores.

1998 ◽  
Vol 16 (1) ◽  
pp. 139-144 ◽  
Author(s):  
D Osoba ◽  
G Rodrigues ◽  
J Myles ◽  
B Zee ◽  
J Pater
Keyword(s):  
Quality Of Life ◽  
Effect Sizes ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
European Organization ◽  
Global Quality Of Life ◽  
Related Quality ◽  
Health Related ◽  
The Mean

PURPOSE To determine the significance to patients of changes in health-related quality-of-life (HLQ) scores assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). PATIENTS AND METHODS A subjective significance questionnaire (SSQ), which asks patients about perceived changes in physical, emotional, and social functioning and in global quality of life (global QL) and the QLQ-C30 were completed by patients who received chemotherapy for either breast cancer or small-cell lung cancer (SCLC). In the SSQ, patients rated their perception of change since the last time they completed the QLQ-C30 using a 7-category scale that ranged from "much worse" through "no change" to "much better." For each category of change in the SSQ, the corresponding differences were calculated in QLQ-C30 mean scores and effect sizes were determined. RESULTS For patients who indicated "no change" in the SSQ, the mean change in scores in the corresponding QLQ-C30 domains was not significantly different from 0. For patients who indicated "a little" change either for better or for worse, the mean change in scores was about 5 to 10; for "moderate" change, about 10 to 20; and for "very much" change, greater than 20. Effect sizes increased in concordance with increasing changes in SSQ ratings and QLQ-C30 scores. CONCLUSION The significance of changes in QLQ-C30 scores can be interpreted in terms of small, moderate, or large changes in quality of life as reported by patients in the SSQ. The magnitude of these changes also can be used to calculate the sample sizes required to detect a specified change in clinical trials.

scholarly journals HEALTH-RELATED QUALITY OF LIFE AND THERAPEUTIC ADHERENCE IN BREAST AND PROSTATE CANCER

2021 ◽  
Vol 30 ◽  
Author(s):  
Lia Raquel de Carvalho Viana ◽  
Cláudia Jeane Lopes Pimenta ◽  
Gerlania Rodrigues Salviano Ferreira ◽  
Jacira dos Santos Oliveira ◽  
Tatiana Ferreira da Costa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Statistical Significance ◽  
Subjective Norms ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Breast And Prostate Cancer

ABSTRACT Objective to correlate health-related quality of life and adherence to treatment of patients with breast and prostate cancer. Method an exploratory, descriptive and cross-sectional study, with a quantitative approach, conducted with 305 patients with breast and prostate cancer, in a state oncology hospital in Paraíba, Brazil, between June and November 2019. For data collection, a semi-structured instrument was used to obtain data regarding the sociodemographic and clinical profile, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire “core” 30 items, from the specific module Quality of Life Questionnaire-Breast Cancer, and from the Adherence Determinants Questionnaire. Data analysis was performed using descriptive and inferential statistics. Results the correlation between health-related quality of life and adherence of patients with prostate cancer showed statistical significance (p≤0.05) between the Global health Scale and the Functional Scale, Intentions domain; emotional function and intentions; insomnia and subjective norms; financial difficulty and subjective norms. In women, there was statistical significance (p≤0.05) between role performance and subjective norms; fatigue and intentions; financial difficulty and total adherence; sexual desire, sexual satisfaction and perceived support/severity; breast symptoms and intentions. Conclusion health-related quality of life directly impacts on treatment adherence of patients with breast and prostate cancer.

Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias

2003 ◽  
Vol 91 (1) ◽  
pp. 9-13 ◽  
Author(s):  
M.S. Litwin ◽  
C.S. Saigal ◽  
D.P. Lubeck ◽  
Y.-P. Li ◽  
J.M. Henning ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Lead Time ◽  
Metastatic Prostate Cancer ◽  
Health Related Quality ◽  
Lead Time Bias ◽  
Related Quality ◽  
Health Related

scholarly journals Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA)

2016 ◽  
Vol 17 (2) ◽  
pp. 388-400 ◽  
Author(s):  
Maja S. Sommer ◽  
Karen Trier ◽  
Jette Vibe-Petersen ◽  
Karl B. Christensen ◽  
Malene Missel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Well Being ◽  
Rehabilitation Program ◽  
Health Related Quality ◽  
Global Quality ◽  
Global Quality Of Life ◽  
Related Quality ◽  
Health Related

Introduction: Surgical resection in patients with non–small cell lung cancer (NSCLC) may be associated with significant morbidity, functional limitations, and decreased quality of life. Objectives: The objective is to present health-related quality of life (HRQoL) changes over time before and 1 year after surgery in patients with NSCLC participating in a rehabilitation program. Methods: Forty patients with NSCLC in disease stage I to IIIa, referred for surgical resection at the Department of Cardiothoracic Surgery RT, Rigshospitalet, were included in the study. The rehabilitation program comprised supervised group exercise program, 2 hours weekly for 12 weeks, combined with individual counseling. The study endpoints were self-reported HRQoL (Functional Assessment of Cancer Therapy–Lung, European Organization for Research and Treatment in Cancer–Quality of Life Questionnaire-QLQ-C30, Short-Form-36) and self-reported distress, anxiety, depression, and social support (National Comprehensive Cancer Network Distress Thermometer, Hospital Anxiety and Depression Scale, Multidimensional Scale of Perceived Social Support), measured presurgery, postintervention, 6 months, and 1 year after surgery. Results: Forty patients were included, 73% of whom completed rehabilitation. Results on emotional well-being ( P < .0001), global quality of life ( P = .0032), and mental health component score ( P = .0004) showed an overall statistically significant improvement during the study. Conclusion: This feasibility study demonstrated that global quality of life, mental health, and emotional well-being improved significantly during the study, from time of diagnosis until 1 year after resection, in patients with NSCLC participating in rehabilitation.

Sign in / Sign up

Export Citation Format

Share Document